The effect of spironolactone in patients with obesity at risk for heart failure: proteomic insights from the HOMAGE trial.
Fiche publication
Date publication
décembre 2021
Journal
Journal of cardiac failure
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Verdonschot JAJ, Ferreira JP, Pizard A, Pellicori P, La Rocca HB, Clark AL, Cosmi F, Cuthbert J, Girerd N, Waring OJ, Henkens MHTM, Mariottoni B, Petutschnigg J, Rossignol P, Hazebroek MR, Cleland JGF, Zannad F, Heymans SRB,
Lien Pubmed
Résumé
Adipose tissue influences the expression and degradation of circulating biomarkers. We aimed to identify the biomarker profile and biological meaning of biomarkers associated with obesity, to assess the effect of spironolactone on the circulating biomarkers, and to explore whether obesity might modify the effect of spironolactone.
Mots clés
biomarker, heart failure, obesity, spironolactone
Référence
J Card Fail. 2021 Dec 18;: